CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Androgel 10 grams of gel containing 100 mg of testosteronedrug
Likely dose
Androgel 10 grams of gel containing 100 mg of testosteronefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00405353
NCT00405353Phase 2Completed
CompareCT.gov

Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial

University of California, Los Angeles·interventional·Posted Nov 30, 2006·Updated Nov 22, 2019

In Brief

A Phase 2 clinical trial evaluating Androgel 10 grams of gel containing 100 mg of testosterone for Multiple Sclerosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsNational Multiple Sclerosis Society

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 30, 2006
Enrollment StartApr 1, 2002
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 19.6 years ago

Interventions

Androgel 10 grams of gel containing 100 mg of testosteronedrug

testosterone gel